8-K Announcements
6Material company update
Apr 8, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Mar 6, 2026·SEC
Drugs Made In America Acquisition Corp. Ordinary Shares(DMAA)Earnings, Financials & Key Ratios
DMAA•NASDAQ•Banking & Credit
$10.60
$111M mkt cap·Price updated May 7, 2026
SectorFinancial ServicesIndustrySPACs & Shell CompaniesSub-IndustryHealthcare and life sciences SPACs
AboutDrugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.Show more
- Net Interest Income$0
- Total Revenue$0
- Net Income-$479
- Net Interest Margin0%
- ROA-86.96%
- Equity / Assets-44.28%
- Book Value per Share-0.00
- Tangible BV/Share-0.00
DMAA Key Insights
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Thin capital base
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
DMAA Price & Volume
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) stock price & volume — 10-year historical chart
Loading chart...
DMAA Peer Comparison
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) competitors in Healthcare and life sciences SPACs — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HCAI | 15.68M | 14.50 | 9.71 | 19.45% | 5.48% | 0.42 | ||
 BRTX | 1.8M | 0.23 | -0.19 | 175.03% | -33.05% | -5.74% | ||
 NUVB | 1.67B | 4.82 | -8.03 | 6.99% | -102.06% | -44.1% | 0.03 | |
 MRK | 277.34B | 112.29 | 15.42 | 1.18% | 28.12% | 36.14% | 0.96 | |
 PFE | 150.63B | 26.48 | 19.47 | -1.65% | 11.83% | 8.34% | 0.78 | |
 ABBV | 358.42B | 202.64 | 85.50 | 8.57% | 6.91% | 62.15% | ||
 BMY | 114.85B | 56.25 | 16.30 | -0.22% | 15.01% | 38.96% | 2.55 | |
 LLY | 921.16B | 974.96 | 42.48 | 44.7% | 34.98% | 101.17% | 1.60 |
Compare DMAA vs Peers
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DMAA Income Statement
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'24 | TTM |
|---|---|---|
| Net Interest Income | 0 | 4.01M |
| NII Growth % | - | 0% |
| Net Interest Margin % | 0% | 1.69% |
| Interest Income | 0 | 4.01M |
| Interest Expense | 0 | 0 |
| Loan Loss Provision | 0 | 0 |
| Non-Interest Income | 0 | -4.01M |
| Non-Interest Income % | - | - |
| Total Revenue | 0▲ 0% | 0▲ 0% |
| Revenue Growth % | - | 0% |
| Non-Interest Expense | 480 | 726.83K |
| Efficiency Ratio | - | - |
| Operating Income | -479▲ 0% | -726.83K▲ 0% |
| Operating Margin % | - | - |
| Operating Income Growth % | - | - |
| Pretax Income | -479▲ 0% | 5.73M▲ 0% |
| Pretax Margin % | - | - |
| Income Tax | 0 | 0 |
| Effective Tax Rate % | 0% | 0% |
| Net Income | -479▲ 0% | 5.73M▲ 0% |
| Net Margin % | - | - |
| Net Income Growth % | - | - |
| Net Income (Continuing) | -479 | 5.73M |
| EPS (Diluted) | -0.06▲ 0% | 0.25▲ 0% |
| EPS Growth % | - | - |
| EPS (Basic) | -0.06 | - |
| Diluted Shares Outstanding | 8.57M | 23M |
DMAA Balance Sheet
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'24 | TTM |
|---|---|---|
| Cash & Short Term Investments | 1.35K | 3.81K |
| Cash & Due from Banks | 1.35K | 717 |
| Short Term Investments | 0 | 0 |
| Total Investments | 0 | 0 |
| Investments Growth % | - | 0% |
| Long-Term Investments | 0 | 469.44M |
| Accounts Receivables | 0 | 0 |
| Goodwill & Intangibles | 0 | 0 |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| PP&E (Net) | 0 | 0 |
| Other Assets | 546 | 237.6M |
| Total Current Assets | 4.99K | 28.2K |
| Total Non-Current Assets | 546 | 237.6M |
| Total Assets | 551▲ 0% | 237.63M▲ 0% |
| Asset Growth % | - | 100055564.06% |
| Return on Assets (ROA) | -86.96% | 2.41% |
| Accounts Payable | 0 | 0 |
| Total Debt | 662 | 0 |
| Net Debt | 661 | -717 |
| Long-Term Debt | 0 | 0 |
| Short-Term Debt | 662 | 0 |
| Other Liabilities | 0 | 6.9M |
| Total Current Liabilities | 796 | 456.61K |
| Total Non-Current Liabilities | 0 | 6.9M |
| Total Liabilities | 796 | 7.36M |
| Total Equity | -244▲ 0% | -7.33M▲ 0% |
| Equity Growth % | - | 99995554.74% |
| Equity / Assets (Capital Ratio) | -44.28% | -3.08% |
| Return on Equity (ROE) | - | 5.13% |
| Book Value per Share | -0.00 | -0.32 |
| Tangible BV per Share | -0.00 | -0.32 |
| Common Stock | 986 | 237.61M |
| Additional Paid-in Capital | 34 | 0 |
| Retained Earnings | -279 | -6.72M |
| Accumulated OCI | 0 | 0 |
| Treasury Stock | 0 | 0 |
| Preferred Stock | 0 | 0 |
DMAA Cash Flow Statement
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) cash flow — operating, investing & free cash flow history
| Line item | Dec'24 | TTM |
|---|---|---|
| Cash from Operations | -172.26K | -295 |
| Operating CF Growth % | - | -261169.03% |
| Net Income | -479 | 5.73M |
| Depreciation & Amortization | 0 | 0 |
| Deferred Taxes | 0 | 0 |
| Other Non-Cash Items | -171.92K | -6.21M |
| Working Capital Changes | 132 | 69.88K |
| Cash from Investing | 0 | -231.15M |
| Purchase of Investments | 0 | 0 |
| Sale/Maturity of Investments | 0 | 0 |
| Net Investment Activity | 0 | 0 |
| Acquisitions | 0 | 0 |
| Other Investing | 0 | -231.15M |
| Cash from Financing | 173.62K | 231.56M |
| Dividends Paid | 0 | 0 |
| Share Repurchases | 0 | 0 |
| Stock Issued | -328.6K | -638 |
| Net Stock Activity | -328.6K | -638 |
| Debt Issuance (Net) | 502.21K | -900K |
| Other Financing | 0 | 413.37K |
| Net Change in Cash | 1.35K▲ 0% | -2.55K▲ 0% |
| Exchange Rate Effect | 0 | 0 |
| Cash at Beginning | 0 | 822 |
| Cash at End | 1.35K | 717 |
| Interest Paid | 0 | 0 |
| Income Taxes Paid | 0 | 0 |
| Free Cash Flow | -295▲ 0% | -414.13K▲ 0% |
| FCF Growth % | - | - |
DMAA Banking Ratios
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | TTM |
|---|---|
| Return on Equity (ROE) | 5.13% |
| Return on Assets (ROA) | 2.41% |
| Net Interest Margin | 1.69% |
| Equity / Assets | -3.08% |
| Book Value / Share | -0.32 |
| Dividend Payout | 0% |
DMAA SEC Filings & Documents
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) SEC filings — annual & quarterly reports (10-K, 10-Q)
DMAA Frequently Asked Questions
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is profitable, generating $5.7M in net income for fiscal year 2024.
Industry Metrics
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a net interest margin (NIM) of N/A. NIM has been under pressure due to interest rate environment.
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has an efficiency ratio of 0.0%. This is excellent, indicating strong cost control.
Explore More DMAA
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates